Compare SABS & ASYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | ASYS |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.9M | 312.2M |
| IPO Year | 2020 | 2006 |
| Metric | SABS | ASYS |
|---|---|---|
| Price | $3.29 | $12.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $11.64 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 634.0K | 213.8K |
| Earning Date | 11-05-2026 | 12-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.53 | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $79,364,000.00 |
| Revenue This Year | N/A | $7.62 |
| Revenue Next Year | N/A | $26.71 |
| P/E Ratio | ★ N/A | $71.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.44 | $6.75 |
| 52 Week High | $5.15 | $25.71 |
| Indicator | SABS | ASYS |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 38.16 |
| Support Level | $2.44 | $12.05 |
| Resistance Level | $4.06 | $17.91 |
| Average True Range (ATR) | 0.23 | 0.73 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 92.47 | 18.09 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.